Medical Science Liaison required for Ireland

Medical Science Liaison required for Ireland!

At Jackie Brown Medical we have a new requirement for a Medical Science Liaison/ Scientific Product Liaison for an excellent client in Ireland.

The Job:

Acting as the liaison between company and clients, you will establish relationships with opinion leaders including; clinical trial investigators, academic physicians, CF care teams, nurses and patient advocacy group leads.

You will also serve as a scientific expert and advisor on disease state concepts for the company and their products – current and in development.

The Person:

• You will hold a third level degree in Advanced Biomedical Science (DO, MD, PharmD, PhD)
• Have 5 years experience in Medical Affairs within the biotechnology/ pharma industries
• Be an experience MSL with a thorough understanding of the biopharmaceutical industry.
• Have an ability to effectively present clinical/ scientific  information in a group or indivisual setting.
• Abilility to travel up to 70%
• Have an understanding on government and industry guidelines, regulations, regulationd, laws etc for appropriate interactions with healthcare providers.

For more information on this job or to apply, please goto:

http://www.jackiebrownmedical.ie/jobs_ireland.php?url=jobs&page=2

Science Product Liaison required for Ireland

Science Product Liaison needed for Ireland!

 

 

We have a new requirement in for a Science Product Liaison for Ireland within the Biotechnology industry.

The Job:

Serving as the Resource and Scientific expert on disease state concepts, you will also provide clinical and health information for HCPs and establish relationships with KOL’s to expand much needed research and advisory opportunities.

The Responsibilities:

• Interaction with the medical community
• Serve as an educational resource to HCPs on disease state concepts, including presentations, patricipating in one on one discussions and tailoring discussions to meet specific needs.
• Serve as a liaison between key corporate functional areas and HCPs who express interest in conducting investigator-initiated research.
• Develop productive relationships with thought leaders in the medical community in the group practice setting.
• Serve as a disease state resource and communicate information obtained from field interactions to internal staff.
• Local liaison supporting the conduct of clinical trials, upon specific request of responsible Clinical Operations or Development colleague.

The Person:

• Advanced Biomedical Science Degree (DO, MD, PharmD, PhD)
• 5 years post grad experience in Medical Affairs within Biotech/ Pharma industry
• MSL experience with thorough understanding of the Biopharma industry
• Cystic Fibrosis, pulmonary diseases or Paediatrics experience
• Rare Metabolic Disorders
• An understanding of government and industry guidelines, regulations and laws etc.
• Ability to travel up to 70%
• Valid Drivers licence.

For more information on this exciting opportunity or to apply, please goto:

http://www.jackiebrownmedical.ie/jobs_ireland.php?url=jobs&page=2

Nanoscience gets funding

New Jobs in Irish Nanoscience Research?

Nanoscience research institute CRANN is to create new jobs in Research & Development, leading research projects including cancer research and computer chips.

The majority of these seventeen newly created  positions are to be in the Institute of Molecular Medicine and TCD School of Medicine in conjunction with CRANN. This particular team will be aiming at nanomedical technology in the early diagnosis of cancer.

The remaining 5 positions are to be with Intel as CRANN focuses on developing computer chips for the next generation.
Professor John Boland, Director of CRANN says “Ireland is now globally recognised for it’s expertise in the area of nanoscience, as evidenced by the large amounts of non-exchequer funding we are winning through competitive international research projects.” He goes on to say “Research is a global competition and we need to contuinue to develop our knowledge base and expertise to make Ireland a true innovation centre”

The investment was seen as a “huge vote of confidence” by Professor Dermot Kelleher of TCD School of Medicine.

Chief Science Officers come from a variety of Science backrounds including Pharmacy

Science Officers Lead The Way in Irelands start up and established Pharmaceutical R&D companies. They provide the scientific backbone of R&D, Regulatory affairs and Pharmacovigilence activity where insight and understanding go hand in hand.

A typical Chief Science Officer will  manage and administer the actvities of other medical drug safety officers, science officers and technical personnel involved first hand in project engineering and the management of  other scientists who may also be Pharmacists engaged in the introduction of new drugs which will also involve vigilence reporting and monitoring of ADR’s and PSUR’s.

Irish Pharmaceutical enterprises are highly engaged in the latest Pharmaceutical drug research and development and it is through the technical and scientific know how of science officers that Ireland has gained significant FDI (Foreign Direct  Investment)

Eight out of ten major internationla biopharma and pharmaceutical multinationals have now sited here in Ireland and this is showing no sign of slowing yet despite the economic downturn.

Biopharma R&D

R&D Continues to expand with several major projecst on the cards for Intel, Pfizer and UCD. Major projects involving nanotechnology, Biopharma and Semiconductor manufacturing facilities in Ireland will continue the extensive developments which have taken place in the past five years.

Ireland continues to lead R&D in  numerous sectors including advanced manufacturing on medical device products and as a result science jobs will be in demand across various life science sectors such as QA/RA, Validation, R&D and drug product developments.

Ireland with the backing of major multinational clients such as Intel, Pfizer and Abbotts will be a continuing center of excellence in science and technology as a result and this will be a primary driver in Irelands emergence from recession

3- 5 years from Killing Cancer

Killing Leukaemia has been the objective of  Cancer Research Scientists for decades. Today that objective has come a step closer with the announcement in the international journal, Cancer Research , that TCD in partnership with the University of Sienna have discovered a new drug called PBOX-15 capable of killing cancerous cells in adult patients with poor prognosis.

R&D is still at an early stage however with development of a viable drug between 3- 5 years from being produced according to Professor Mark Lawlor of TCD’S school of medicine. The study itself involved research across the disciplines of molecular, chemistry and biochemistry at TCD together with contributions from Research colleagues in Belfast City Hospital, Siennna and St James Hospital Dublin.

Pfizer completes its takeover of Wyeth

Pfizer’s total Irish investment amounts to over €7  Billion with products as diverse as vaccines, biologics, nutrition and small molecules, and catering for both animal and human healthcare product sectors. The current combined workforce amounts to over 5000 people  but this may be somewhat reduced following the conclusion of the review process which will lead to reductions in R&D, Engineering and support staff.

However, Pfizer has a significant pipe line of biopharmaceutical development products incoporating exploratory treatments for Alzheimers, Diabetes, inflamation and neuroscience.

The vast majority of these conditions are unmet medical conditions which have potentially longterm and lucrative treatment markets and as such hold the promise of  long term future investment in Irish science jobs.